Increased Lung Volume as Controller Therapy for Asthma

Last updated: June 21, 2024
Sponsor: University of Vermont
Overall Status: Completed

Phase

N/A

Condition

Asthma

Treatment

CPAP

Clinical Study ID

NCT02953431
16-061
  • Ages 18-65
  • All Genders

Study Summary

This is an early phase clinical trial to test the efficacy of elevating lung volume with positive expiratory pressure (CPAP) as a controller therapy for asthma in patients with a BMI ≥ 30 kg/m2.

There will be two phases to this trial.

Phase I:

In the first phase we will determine the optimal duration of CPAP that is effective as a controller therapy in asthma. Up to 9 participants will complete this this phase.

Phase II:

The 2nd phase will be a randomized double-blinded controlled trial of Sham CPAP versus CPAP 10 (using the duration of CPAP determined in phase I) as a controller therapy for asthma, and also to determine the effect o airway reactivity in healthy people with a BMI 30 kg/m2 and above. Twenty people with asthma and twenty controls will complete this phase.

Eligibility Criteria

Inclusion

Inclusion Criteria for people with asthma:

  1. Physician diagnosis of asthma

  2. PC20 to methacholine < 16 mg/ml

  3. IgE < 100 IU/ml

  4. Ages 18-65 years

  5. BMI >=30 kg/m2

Inclusion Criteria for controls:

  1. No physician diagnosis of asthma

  2. PC20 to methacholine > 16 mg/ml

  3. IgE < 100 IU/ml

  4. Ages 18-65 years

  5. BMI >=30 kg/m2

Exclusion

Exclusion Criteria:

  1. FEV1 < 60 % predicted

  2. Other significant disease that in the opinion of the investigator would interferewith study.

  3. Inability to perform required testing.

  4. Smoking within last 6 months.

  5. ≥ 20 pack year smoking history

  6. Inability to provide informed consent

  7. Pregnancy

  8. Known obstructive sleep apnea/ high likelihood of obstructive sleep apnea

  9. Asthma exacerbation in the prior 6 weeks

  10. Stoke or heart attack in the prior 3 months

  11. Known aortic aneurysm

  12. Renal failure

  13. A known severe heart, vascular, liver, renal, or hematological disease

  14. Active allergic rhinitis

  15. Recent eye surgery (within the last month)

Study Design

Total Participants: 60
Treatment Group(s): 1
Primary Treatment: CPAP
Phase:
Study Start date:
May 07, 2018
Estimated Completion Date:
December 31, 2023

Study Description

The effect of 10 versus 0 cmH2O CPAP on airways responsiveness to inhaled methacholine will be studied using an adaptive "3+3" phase I/II study design.

Dose Titration Phase (phase I):

The efficacy of 8 hours of CPAP on airway responsiveness will be tested in three subjects.

Efficacy will be defined as a 25% improvement in the impedance response to methacholine in all three subjects. If this occurs in all subjects, shorter durations of CPAP will be studied (4 hours then one hour).

Conversely, if "dose escalation" is required, 3 nights, then 7 nights of CPAP will be studied.

Randomized-controlled study phase (phase II):

Participants will be randomized to CPAP 10 or Sham 0. The duration of CPAP will be determined in the dose titration phase. The effect on response to inhaled methacholine, lung function and asthma control will be determined in patients with asthma and a BMI ≥ 30 kg/m2, and also in healthy controls without asthma

Connect with a study center

  • Vermont Lung Center

    Colchester, Vermont 05446
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.